ABEO Abeona Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABEO

Price (delayed)

$5.725

Market cap

$326.3M

P/E Ratio

4.58

Dividend/share

N/A

EPS

$1.25

Enterprise value

$288.1M

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 59
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 87

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The revenue has soared by 150% since the previous quarter
The company's gross profit has surged by 140% QoQ
The company's quick ratio rose by 18% YoY but it fell by 16% QoQ
The price to earnings (P/E) is 15% higher than the last 4 quarters average of 4.0
Abeona Therapeutics's equity has decreased by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://abeonatherapeutics.com
Peers: MRK

Key stats

What are the main financial stats of ABEO

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
-0.43%
1 week
1.33%
1 month
5.24%
1 year
-1.46%
YTD
8.63%
QTD
27.79%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$14.54M
Gross profit
$10.31M
Operating income
-$90.86M
Net income
$66.14M
Gross margin
70.9%
Net margin
454.9%
The revenue has soared by 150% since the previous quarter
The company's gross profit has surged by 140% QoQ
Abeona Therapeutics's net margin has shrunk by 63% QoQ
ABEO's operating margin has soared by 58% QoQ

Price vs fundamentals

How does ABEO's price correlate with its fundamentals

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
4.58
P/B
2.25
P/S
22.29
EV/EBIT
4.13
EV/EBITDA
3.92
EV/Sales
19.81
The price to earnings (P/E) is 15% higher than the last 4 quarters average of 4.0
ABEO's EPS is down by 7% since the previous quarter
The price to book (P/B) is 33% higher than the last 4 quarters average of 1.7 but 29% lower than the 5-year quarterly average of 3.2
Abeona Therapeutics's equity has decreased by 9% QoQ
The revenue has soared by 150% since the previous quarter
ABEO's P/S is 94% below its last 4 quarters average of 381.8 and 80% below its 5-year quarterly average of 113.4

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on assets has surged by 177% YoY but it fell by 18% QoQ
Abeona Therapeutics's return on equity has surged by 148% YoY but it has decreased by 22% QoQ
ABEO's ROS has dropped by 63% since the previous quarter
The company's return on invested capital fell by 15% QoQ

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets has surged by 100% YoY but it fell by 10% QoQ
The current ratio is up by 20% year-on-year but it has declined by 15% since the previous quarter
Abeona Therapeutics's debt is 84% lower than its equity
Abeona Therapeutics's debt to equity has shrunk by 72% YoY
Abeona Therapeutics's equity has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.